We Are One Seven LLC Sells 300 Shares of Integra Lifesciences Holdings Corp (NASDAQ:IART)

We Are One Seven LLC lessened its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 6.6% in the second quarter, HoldingsChannel.com reports. The fund owned 4,246 shares of the life sciences company’s stock after selling 300 shares during the period. We Are One Seven LLC’s holdings in Integra Lifesciences were worth $237,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Quadrant Capital Group LLC increased its position in Integra Lifesciences by 223.0% during the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 446 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Integra Lifesciences by 120.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock worth $129,000 after purchasing an additional 1,266 shares in the last quarter. World Asset Management Inc acquired a new position in Integra Lifesciences during the 1st quarter worth approximately $217,000. Stanley Laman Group Ltd. acquired a new position in Integra Lifesciences during the 1st quarter worth approximately $223,000. Finally, Zions Bancorporation N.A. acquired a new position in Integra Lifesciences during the 1st quarter worth approximately $229,000. 82.18% of the stock is owned by institutional investors.

In other news, insider Lisa Evoli sold 2,380 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $63.00, for a total transaction of $149,940.00. Following the completion of the sale, the insider now directly owns 2,588 shares in the company, valued at $163,044. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Christian S. Schade sold 15,658 shares of the stock in a transaction on Friday, May 10th. The stock was sold at an average price of $51.56, for a total transaction of $807,326.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 36,844 shares of company stock valued at $2,085,117. 4.50% of the stock is currently owned by corporate insiders.

NASDAQ IART traded down $0.98 on Friday, hitting $62.45. The company’s stock had a trading volume of 64,968 shares, compared to its average volume of 384,310. Integra Lifesciences Holdings Corp has a 1-year low of $42.14 and a 1-year high of $66.41. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. The stock’s 50-day simple moving average is $55.57. The company has a market capitalization of $5.52 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.03 and a beta of 1.07.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.08. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The company had revenue of $383.60 million during the quarter, compared to analysts’ expectations of $373.29 million. During the same period in the prior year, the company posted $0.60 earnings per share. Integra Lifesciences’s revenue for the quarter was up 4.8% compared to the same quarter last year. As a group, research analysts expect that Integra Lifesciences Holdings Corp will post 2.73 earnings per share for the current fiscal year.

IART has been the subject of a number of research analyst reports. JMP Securities upped their price objective on shares of Integra Lifesciences to $75.00 in a research report on Thursday, July 25th. ValuEngine cut shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research report on Thursday. Oppenheimer upped their price target on shares of Integra Lifesciences from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Royal Bank of Canada set a $66.00 price target on shares of Integra Lifesciences and gave the company a “hold” rating in a research report on Friday, July 26th. Finally, BTIG Research set a $70.00 price target on shares of Integra Lifesciences and gave the company a “buy” rating in a research report on Wednesday, July 24th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $61.92.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: Index Funds

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.